Latest Conference Coverage

NeuroVoices: RJ Tesi, MD, on XPro1595 and the Role of TNF Inhibitors in the Alzheimer Field

The president and chief executive officer of INmune bio provided perspective on the need to diversify the Alzheimer treatment landscape and the potential role of TNF inhibitors like XPro1595.

Difference Between Health Equity and Health Disparities in Epilepsy: Elizabeth Felton, MD, PhD

The assistant professor in the Department of Neurology at the University of Wisconsin spoke about the differences between health disparities and health equity in epilepsy care at the 2022 AES Conference. [WATCH TIME: 3 minutes]

Debating Surgery in Genetic Disorders with Epilepsy: Scott Perry, MD

The head of neurosciences at the Jane and John Justin Neurosciences Center of Cook Children’s Medical Center spoke about his experience in a debate on surgery in genetic disorders at the 2022 AES Conference. [WATCH TIME: 3 minutes]

The Definition of a Seizure, Clinical Controversies: Michael Sperling, MD

The Baldwin Keyes professor of neurology at Thomas Jefferson University, spoke with us at the 2022 AES Conference about the definition of a seizure. [WATCH TIME: 3 minutes]

Results from the Subgroup Analysis of BECOME Caregiver Survey: Robert Iannone, MD, MSCE

The executive vice president of Global Head of Research and Development at Jazz Pharmaceuticals, spoke on the results from the BECOME study presented at the 2022 AES Conference. [WATCH TIME: 6 minutes]

Rare Epilepsies, Comorbidities, and Genetic Therapies: Danielle Andrade, MD, MSc, FRCPC

The professor of neurology at the University of Toronto talked about 3 conditions that were discussed during the epilepsy therapies symposium at the 2022 AES Conference. [WATCH TIME: 5 minutes]

Creating Innovative Ways to Improve Alzheimer Disease Prevention: Miia Kivipelto, MD, PhD

The professor of clinical geriatric epidemiology at Karolinska Institutet discussed strategies for lowering the risk of Alzheimer disease, and the new ways to approach prevention. [WATCH TIME: 4 minutes]

Genetic Approaches to Comorbidities in Epilepsy, Dravet Syndrome: Danielle Andrade, MD, MSc, FRCPC

The professor of neurology at the University of Toronto spoke at the 2022 AES Conference about genetic approaches to comorbidities for patients with epilepsy. [WATCH TIME: 5 minutes]

Preventing Epilepsy Through Antiseizure Medication in Tuberous Sclerosis Complex: Gabrielle Rushing, PhD

The director of research at the TSC Alliance spoke with us at the 2022 AES Conference about future research to be conducted on patients with TSC such as the PREVeNT trial. [WATCH TIME: 6 minutes]

Understanding the Long-Term Role of Brain-Derived Neurotrophic Factor Following Lifestyle Changes: Miia Kivipelto, MD, PhD

The professor of clinical geriatric epidemiology at Karolinska Institutet discussed a subgroup analysis of the FINGERS trial and the clinical utility of the precursor to serum brain-derived neurotrophic factor. [WATCH TIME: 3 minutes]

Need for a Multifactoral Approach to Treat Alzheimer Disease: Nicolas Villain, MD

The cognitive and behavioral neurology fellow at Pitié-Salpêtrière Hospital in Paris, France, provided perspective on the reasons to not solely rely on anti-amyloid treatments to treat Alzheimer disease. [WATCH TIME: 3 minutes]

NeuroVoices: Eric Reiman, MD, on Entering a New Era of Prevention in Alzheimer Disease

Sleep Studies Determine Sleep Disorders in Patients with Epilepsy: Milena Pavlova, MD

At the 2022 AES annual meeting, the associate professor at Harvard Medical School and neurologist at the Brigham and Women's Hospital talked about sleep testing for patients with epilepsy. [WATCH TIME: 3 minutes]

Interactions Between Sleep Disorders and Epilepsy in Adults: Milena Pavlova, MD

The associate professor at Harvard Medical School and neurologist at the Brigham and Women's Hospital spoke about sleep disorders and epilepsy in adults at the 2022 AES annual meeting. [WATCH TIME: 5 minutes]

Tempering Expectations on High-Clearance Anti-Amyloid Immunotherapies in Alzheimer Disease: Nicolas Villain, MD

The cognitive and behavioral neurology fellow at Pitié-Salpêtrière Hospital in Paris, France, provided background on a study presented at CTAD 2022 assessing the efficacy of prominent, up-and-coming anti-amyloid therapies. [WATCH TIME: 7 minutes]

NeuroVoices: Miia Kivipelto, MD, PhD, on Using Multidomain Interventions to Prevent Cognitive Decline

The professor of clinical geriatric epidemiology at Karolinska Institutet provided perspective on the FINGERS trial, the first study to show it is possible to prevent cognitive decline using a multidomain lifestyle intervention.

Understanding the Safety Profile of ALZ-801 in High-Risk Alzheimer Disease: Susan Abushakra, MD

The chief medical officer of Alzheon detailed the phase 2 safety findings of ALZ-801, and the lack of amyloid-related imaging abnormalities observed. [WATCH TIME: 3 minutes]

Recognizing Health Disparities in Infantile Spasms at Local and National Levels: Kerri Neville, MD

The pediatric neurologist and epileptologist at the University of Michigan's Mott Children's Hospital spoke at the 2022 AES conference about disparities that currently exist in epilepsy care. [WATCH TIME: 4 minutes]

Improving Biomarker Selection and Treating the Underlying Pathology of Dementia With Lewy Bodies

James Galvin, MD, MPH, director of the Comprehensive Center for Brain Health at the University of Miami Miller School of Medicine, provided insight on the unmet needs for dementia with Lewy bodies, and whether success in Alzheimer disease can help.

Understanding Irsenontrine’s Role Among Neurodegenerative Disorders: Michael Irizarry, MD, PhD

Institutional Perspectives in Neurology, Chaired by Robert Bermel, MD

Chaired by Robert Bermel, MD, of Cleveland Clinic, the presentations also feature Jeffrey Cohen, MD; Amy Kunchock, MBBS, MMed; and Brandon Moss, MD. [WATCH TIME: 1 hour, 30 minutes]

Sudden Unexpected Death in Epilepsy Linked With Sleep: Sanjeev Kothare, MD

The division director of pediatric neurology, and director of the pediatric sleep program at Cohen, Children's Medical Center, Northwell Health, spoke about sudden unexpected death in epilepsy and sleep at the 2022 AES Conference. [WATCH TIME: 3 minutes]

The Relationship Between Sleep Disorders, Pediatric Epilepsy, and AntiSeizure Medications: Sanjeev Kothare, MD

The division director of pediatric neurology, and director of the pediatric sleep program at Cohen Children's Medical Center of Northwell Health, spoke about the association between sleep disorders and pediatric epilepsy at the 2022 AES annual meeting. [WATCH TIME: 3 minutes]

Integrating Machine Learning, Digital Platforms to Alzheimer Trials: David Bates, PhD

The chief executive officer and co-founder of Linus Health discussed screening tools for early cognitive decline and overcoming the complexities with using new-age technology. [WATCH TIME: 3 minutes]

NeuroVoices: Susan Abushakra, MD, on the Potential Role of ALZ-801 Within the Alzheimer Treatment Landscape

The chief medical officer of Alzheon detailed the efficacy, safety, and potential of ALZ-801, an investigational anti-amyloid therapy being assessed in high-risk individuals with early Alzheimer disease.

Significance of ALZ-801’s Impact on Carriers of APOE e4 Alleles: Susan Abushakra, MD

The chief medical officer of Alzheon discussed the impact a therapy like ALZ-801 can have on the overall Alzheimer community considering its effects on carriers of APOE e4 alleles. [WATCH TIME: 3 minutes]

Hydromethylthionine Mesylate’s Place as a Potential Tau Aggregator of Alzheimer Disease

Bjoern Schelter, MD, Data Analytics and Biostatistics lead at TauRx, provided background on the efficacy, safety, and role of HMTM as a treatment for cognition in pre-Alzheimer disease stages like mild cognitive impairment.

Partnering Clinicians With Parents as a Motivator for Pediatric Epilepsy Research: Zachary Grinspan, MD, MS

Fueling Research Focused on Improving Diagnosis and Therapeutics in Alzheimer Disease

Howard Fillit, MD, founding executive director of the Alzheimer’s Drug Discovery Foundation, provided perspective on how ADDF and others are advancing the detection and treatment of Alzheimer disease.

Continuing to Advance Alzheimer Clinical Trial Design Through Technology: David Bates, PhD

The chief executive officer and co-founder of Linus Health provided perspective on the state of clinical trials for Alzheimer disease, and how technology can play a major role in advancing therapeutics going forward. [WATCH TIME: 4 minutes]